Xarelto(Bayer/Janssen) initiates trial for non valvular Atrial Fibrillation
Bayer HealthCare announced the initiation of the PIONEER AF-PCI study, a Phase IIIb clinical study of its oral anticoagulant Xarelto (rivaroxaban) to investigate how best to treat patients with non-valvular Atrial Fibrillation who undergo Percutaneous Coronary Intervention with stent placement.
The PIONEER AF-PCI study will enroll approximately 2,100 patients worldwide. The trial will assess the safety of two rivaroxaban treatment strategies and a dose-adjusted vitamin K antagonist treatment strategy. Patients will be treated for 12 months.
Other trials for Xarelto are COMPASS investigating Xarelto in 20,000 patients with CAD or peripheral artery disease, while X-VeRT is evaluating 1,500 patients with Atrial Fibrillation scheduled for Cardioversion, a procedure to convert abnormally fast heart rate to a normal rhythm.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins